Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03526328 · ClinicalTrials.gov registry record
DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma
A clinical trial of Esophageal Adenocarcinoma and Barrett's Esophagus, sponsored by University of Oklahoma.
- Completed
- Registry status
- 32
- Enrollment target
- 1
- Study location
NCT03526328: Completed study of Esophageal Adenocarcinoma and Barrett's Esophagus, sponsored by University of Oklahoma.
NCT03526328 is a study of Esophageal Adenocarcinoma and Barrett's Esophagus that has completed, run by University of Oklahoma. The registered enrollment target is 32 participants, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03526328, a study of Esophageal Adenocarcinoma and Barrett's Esophagus, has completed, sponsored by University of Oklahoma.
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypotheses are: 1) the intestinal stem cell marker, DCLK1, which is increased in both the epithelium and stroma in colon cancer is also increased in BE (Barrett's esophagus) with HGD (high grade dysplasia) and in EAC (esophageal adenocarcinoma), 2) this expression correlates with disease progression towards EAC and 3) eradication of cells expressing stem cell markers occurs after therapy of EMR (endoscopic mucosal resection) or RFA (radiofrequency ablation) to eradicate BE with HGD and intramucosal adenocarcinoma and esophagectomy for EAC. We will test our hypotheses with the following aims: 1) To characterize the cell specific expression patterns of intestinal stem cell biomarkers in BE patients and correlate them with serum expression and disease progression, 2) To examine prospectively the effects of EMR, RFA or esophagectomy on the expression of stem cell biomarkers and the progression to EAC.
Primary Outcome
Exploratory; analysis of expression of various markers for Barrett's esophagus and esophogeal adenocarcinoma
Conditions Studied
Interventions
- OTHER EMR and RFA effect on stem cell marker expression in BE/EAC
Study Locations (1)
Oklahoma
- Gastroenterology - Oklahoma City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-03 |
| Est. Completion | 2019-08-13 |
What the finished NCT03526328 record still lists
NCT03526328 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (90% lower).
The record links to 2 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which EMR and RFA effect on stem cell marker expression in BE/EAC is the first listed.
NCT03526328 reports a single indexed study location in Oklahoma.
Frequently Asked Questions
What is clinical trial NCT03526328 about?
NCT03526328 is a clinical study titled "DCLK1 as a Marker/Indicator of Stem Cell Response in Barrett's Esophagus/Esophageal Adenocarcinoma". The hypotheses are: 1) the intestinal stem cell marker, DCLK1, which is increased in both the epithelium and stroma in colon cancer is also increased in BE (Barrett's esophagus) with HGD (high grade dysplasia) and in EAC (esophageal adenocarcinoma), 2) this expression correlates with disease progres...
What is the current status of trial NCT03526328?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2013-03. Estimated completion is 2019-08-13.
What conditions does trial NCT03526328 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett's Esophagus.
What interventions are being tested in trial NCT03526328?
The interventions under investigation include: EMR and RFA effect on stem cell marker expression in BE/EAC (OTHER).
Who is sponsoring clinical trial NCT03526328?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03526328 being conducted?
This trial has 1 study location across Oklahoma. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03526328's enrollment target sits among peer trials
32 33rd of 43 higher than 11 of 43 other Esophageal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
RECRUITING · Phase 2
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Progression of Gastroesophageal Reflux Disease and Barrett's Esophagus and the Creation of a Barrett's Registry
RECRUITING
-
Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)
RECRUITING · Phase 2
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia